293
Views
36
CrossRef citations to date
0
Altmetric
Research Article

Innate immunity proteins in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis

, , , &
Pages 373-380 | Received 21 Dec 2009, Accepted 09 Feb 2010, Published online: 24 Jul 2010
 

ABSTRACT

Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) may be caused by epithelial cell injury. Epithelial cells respond to injury by secreting innate immunity proteins. To investigate whether altered levels of innate immunity proteins are observed in COPD and IPF, the authors assessed secretory leukocyte protease inhibitor (SLPI), elafin, CC16, and β-defensin-2 levels by enzyme-linked immunosorbent assay (ELISA) in sputum supernatants from COPD patients (n = 19), smokers without COPD (n = 21), and never-smokers (n = 10) and in BALF supernatants from patients with IPF (n = 11) and subjects without IPF (n = 11). CC16 levels were decreased, whereas SLPI and elafin levels were increased in COPD patients (0.8 [0–4.2] μg/mL, 2.5 [0.3–10.5] μg/mL, 213 [152–318] pg/mL, respectively) compared to smokers without COPD (1.8 [0.1–21.2] μg/mL, 0.8 [0.2–2.6] μg/mL, 172 [71–473] pg/mL, respectively) and never-smokers (0.5 [0–4.8] μg/mL, 0.1 [0.05–0.6] μg/mL, 188 [129–218] pg/mL, respectively) (CC16: P = .001; SLPI: P <.001; elafin: P = .041). β-Defensin-2 was detected in smokers without COPD (98 [10–729] pg/mL) and never-smokers (74 [35–410] pg/mL), but not in COPD. SLPI and elafin levels did not differ between IPF patients and controls, but CC16 levels were increased in IPF (0.5 [0–2.3] versus 0.2 [0–0.3] μg/mL; P = .019). β-Defensin-2 was not detected in BALF. In conclusion, in COPD, secretion of CC16 and β-defensin-2 might be suppressed, whereas SLPI and elafin secretion is up-regulated. In IPF, only CC16 secretion is up-regulated.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.